Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This qualitative single-center study maps St. Jude’s replacement of routine conventional cytogenetics with clinical genomics for pediatric ALL diagnosis and identifies implementation lessons, perceived benefits, and institutional risks.
The reported evidence supports the feasibility of cytogenetics de-implementation at one institution; by inference, genomics-centered diagnostic workflows could improve classification and resource use and potentially inform treatment selection, but the record provides no direct evidence of improved treatment outcomes.
This multicenter Swiss cross-sectional survey of 103 bereaved parents identified low-, moderate-, and high-grief profiles and found greater grief intensity associated with poverty risk and a child's death in a healthcare facility, while longer time since death was associated with lower intensity.
The study provides observational evidence for persistent grief and potential risk markers; it supports the inference— not tested here—that early identification and sustained, targeted bereavement support for higher-risk parents could reduce long-term grief burden.
This review summarizes aromatase-inhibitor pharmacology and male use, reporting generally reduced estradiol and increased gonadotropins and testosterone but inconsistent clinical benefit, substantial response heterogeneity, and unresolved skeletal and developmental risks in adolescent boys.
The supplied evidence supports predictable endocrine modulation by aromatase inhibition, but it does not establish a pediatric-oncology treatment strategy; at most, it suggests the inference that estrogen suppression and associated skeletal or developmental effects warrant study and monitoring in relevant adolescent oncology populations.
This prospective cross-sectional study found reduced choroidal thickness at most measured locations in children after surgery for adamantinomatous craniopharyngioma compared with matched healthy controls, with exploratory associations involving place of birth and cavernous sinus infiltration.
The evidence supports postoperative choroidal thinning as a potential ocular correlate of pediatric craniopharyngioma or its treatment; it remains an untested inference that serial OCT measurements could help monitor optic-pathway injury, microvascular changes, or treatment effects and thereby guide supportive ophthalmic care.
The paper reports CoPath, a lightweight contrastive multi-scale framework that uses pathology-informed voting to subtype peripheral neuroblastic tumors from hematoxylin-eosin whole-slide images, with reported competitive or superior classification performance and lower computational complexity than comparator models.
Evidence in the record supports CoPath as a diagnostic and pathological-subtyping tool; it may indirectly improve treatment selection by supporting risk stratification, but no evidence is provided that its use changes therapy, toxicity, survival, or other patient outcomes.
This pooled analysis of 10 cross-sectional surveys estimated substantial 2023 health and financial burdens attributable to adverse childhood experiences among adults in England and Wales, including burden across several disease categories such as cancer.
The evidence supports ACE prevention and support services as potential public-health priorities; it does not test an intervention or establish that such measures prevent pediatric cancer or improve pediatric-oncology outcomes, so any oncology benefit remains an indirect inference.
In a cross-sectional survey of 390 Chinese breast cancer survivors aged 18–49 years, poorer psychosocial adaptation was associated with greater existential distress, with social support and psychological resilience statistically mediating part of this relationship.
The evidence supports associations and statistical mediation, not causality; it suggests the testable hypothesis that interventions strengthening social support and psychological resilience could reduce existential distress during breast cancer rehabilitation.
In a nationwide cross-sectional survey of 163,433 Indonesian women aged 15–49 years, 8.7% reported cervical cancer screening, with information exposure showing the strongest association with uptake (OR 2.252, 95% CI 1.992–2.545).
The evidence shows associations between screening uptake and information exposure, age, education, occupation, insurance, and parity; it supports—but does not establish—that targeted education and access interventions could increase screening and potentially improve cervical cancer prevention.
This review summarizes pediatric genetic and acquired hypophosphatemic rickets, proposes an algorithm distinguishing FGF23-dependent from FGF23-independent disease, and outlines conventional and targeted therapies including burosumab.
The record supports FGF23-based diagnostic stratification and identifies burosumab as a targeted therapy for FGF23-mediated disease; it is reasonable but unproven from this review alone to infer that earlier algorithm-guided classification could improve treatment selection and outcomes, including recognition of rare tumor-induced osteomalacia.
In a retrospective clinical cohort of 98 pediatric patients, cognitive performance did not significantly differ between children with NF1 with versus without optic pathway glioma, while both NF1 groups showed weaker reasoning performance than children with non-NF1 visual-system tumors.
The study provides observational evidence that NF1-associated cognitive vulnerability may be more closely related to the underlying disorder than to additional OPG burden; by inference, routine neuropsychological monitoring based on NF1 status rather than OPG status alone could support earlier educational or rehabilitative intervention, but no treatment effect was tested.
This commentary describes a Canadian multi-phase initiative using a Plan-Do-Study-Act quality-improvement framework to develop and test education and program-delivery strategies intended to increase HPV vaccination in school-based programs.
The record supports the use of PDSA as an implementation framework, but reports no vaccination-uptake or cancer outcomes; it can only be inferred that iterative, locally tailored delivery strategies may increase HPV immunization and thereby contribute to long-term prevention of HPV-associated cancers.
In a community-engaged, two-round Delphi study, 129 parents and 62 pediatric oncology providers differed in how they framed the consequences of unmet psychosocial, financial, and neurocognitive monitoring standards, while supporting frequent, structured assessment.
The study provides stakeholder evidence favoring structured monitoring of psychosocial, financial, and neurocognitive needs; it is reasonable—but not demonstrated here—to hypothesize that implementing such monitoring could enable earlier supportive interventions and improve patient or family outcomes.
